CSRXP: FINALIZED CMS COVERAGE DECISION FOR ADUHELM PROTECTS SENIORS AND TAXPAYERS FROM BIG PHARMA PRICE-GOUGING
Decision Appropriately Balances Access to Treatment with the Need for More… Read More
Decision Appropriately Balances Access to Treatment with the Need for More… Read More
Lawmakers Must Deliver on Repeated Promises to Hold Big Pharma Accountable… Read More
FDA Can Play a Critical Role in Holding Big Pharma Accountable and Promoting… Read More
Broad Majorities of Americans Blame Pharmaceutical Industry for Out-of-Control… Read More
Drug Companies Increased Prices on 785 Brand Name Products in First Month of… Read More
DECISION WILL HELP PROTECT SENIORS, TAXPAYERS AND THE U.S. HEALTH SYSTEM FROM… Read More
Next FDA Commissioner Must Promote Competition, Transparency And Value In The… Read More
Fourth Major Round Of Pandemic Price Hikes Highlight Urgency for Policymakers… Read More
U.S. House Oversight & Reform Committee Report Finds Big Pharma’s… Read More
Congress Must Capitalize on Historic Opportunity to Lower Drug Prices… Read More
Biogen’s Staggering $56,000 Price Tag for Treatment With No Proven Clinical… Read More
Congress Should Reject Pharma-backed Proposals That Would Hike Health Care… Read More